$QBIO Uttroside-B - Liver Cancer Chemotherapeutic
We are developing an innovative treatment for liver cancer, a disease indication that currently has a high unmet need. Currently, there are only two approved first-line therapies. We licensed and have advanced Uttroside-B, a new molecule that showed ten times the potency of the current standard of care in early pre-clinical investigation. Uttroside-B was discovered in the leaf of the Black Nightshade plant in India. As it is not feasible to use the plant as the source for a drug, we successfully synthesized the molecule thereby creating an exact replica of the naturally occurring chemical compound. We are now preparing to advance this into a pre-clinical program and have recently been awarded Orphan Drug designation. Manufacturing and scale-up of the drug for use in preclinical testing and IND application has begun. Pre-clinical testing is underway and early results are encouraging.
Corporate Strategic Goals
Our mission is to solve problems by accelerating the development of important therapies and availability of those therapies to patients. We believe we are creating value for our shareholders as we approach some milestones and catalysts. In particular we are very encouraged by the de-risking of the Mannin platform with significant non-dilutive funding to support the clinical program and potential for licensing opportunities in multiple therapeutic areas over the next 12 months. This along with the growth in the Strontium revenue and addition of potential products in the same vertical could provide meaningful revenue opportunities over the next 6 – 24 months.
The funding we have raised to date has allowed us to settle some outstanding payables, prepare for an uplisting on a senior exchange and to continue developing our current assets. The uplisting will coincide with a proposed capital raise that, in the minimum, will satisfy our next 12 month capital needs. Our priority is to continue to support and expand a contract sales force for Strontium-89 in commercial and federal settings and possibly increase the product offering in this nuclear medicine vertical. We will also focus on advancing our rare disease portfolio in liver cancer, and leveraging the now almost $20,000,000 in committed non-dilutive government funding for the Mannin platform of vascular therapeutics for Acute Respiratory Distress Syndrome for COVID-19 patients as well as Glaucoma, Kidney diseases and others.
We believe our current valuation is not reflective of the opportunity within our pipeline. The pandemic environment has certainly made our job much harder, but that does not allow us to avoid blame for some missteps along the way. We have learned much about our business and the 'new normal' in which we have to operate and what we think will make our current opportunities more valuable to the market. We continue to believe that we have created a valuable and exciting company and expect to see that translate over the next 12 months as we approach several significant milestones. We are resilient and better prepared for our future than ever before.
About Q BioMed Inc.
Q BioMed Inc is a biotech acceleration and commercial stage company. Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need?.
Please visit http://www.QBioMed.com and sign up for regular updates.
We are developing an innovative treatment for liver cancer, a disease indication that currently has a high unmet need. Currently, there are only two approved first-line therapies. We licensed and have advanced Uttroside-B, a new molecule that showed ten times the potency of the current standard of care in early pre-clinical investigation. Uttroside-B was discovered in the leaf of the Black Nightshade plant in India. As it is not feasible to use the plant as the source for a drug, we successfully synthesized the molecule thereby creating an exact replica of the naturally occurring chemical compound. We are now preparing to advance this into a pre-clinical program and have recently been awarded Orphan Drug designation. Manufacturing and scale-up of the drug for use in preclinical testing and IND application has begun. Pre-clinical testing is underway and early results are encouraging.
Corporate Strategic Goals
Our mission is to solve problems by accelerating the development of important therapies and availability of those therapies to patients. We believe we are creating value for our shareholders as we approach some milestones and catalysts. In particular we are very encouraged by the de-risking of the Mannin platform with significant non-dilutive funding to support the clinical program and potential for licensing opportunities in multiple therapeutic areas over the next 12 months. This along with the growth in the Strontium revenue and addition of potential products in the same vertical could provide meaningful revenue opportunities over the next 6 – 24 months.
The funding we have raised to date has allowed us to settle some outstanding payables, prepare for an uplisting on a senior exchange and to continue developing our current assets. The uplisting will coincide with a proposed capital raise that, in the minimum, will satisfy our next 12 month capital needs. Our priority is to continue to support and expand a contract sales force for Strontium-89 in commercial and federal settings and possibly increase the product offering in this nuclear medicine vertical. We will also focus on advancing our rare disease portfolio in liver cancer, and leveraging the now almost $20,000,000 in committed non-dilutive government funding for the Mannin platform of vascular therapeutics for Acute Respiratory Distress Syndrome for COVID-19 patients as well as Glaucoma, Kidney diseases and others.
We believe our current valuation is not reflective of the opportunity within our pipeline. The pandemic environment has certainly made our job much harder, but that does not allow us to avoid blame for some missteps along the way. We have learned much about our business and the 'new normal' in which we have to operate and what we think will make our current opportunities more valuable to the market. We continue to believe that we have created a valuable and exciting company and expect to see that translate over the next 12 months as we approach several significant milestones. We are resilient and better prepared for our future than ever before.
About Q BioMed Inc.
Q BioMed Inc is a biotech acceleration and commercial stage company. Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need?.
Please visit http://www.QBioMed.com and sign up for regular updates.
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
